Seemay Chou (tech billionaire and scientist) is embarking on a mission to reshape the landscape of biological research through her new nonprofit, Radial. Backed by a $3.5 billion commitment, Chou aims to dismantle the data bottlenecks that currently hinder the development of advanced artificial intelligence in medicine.

Central to this initiative is the Diffuse project, an ambitious effort to construct a comprehensive structural biology database. By providing high-quality, standardized datasets, the project seeks to provide the foundational "fuel" required for the next generation of predictive models. Chou believes that the scarcity of organized biological data is the primary hurdle preventing a second "AlphaFold moment" in other scientific fields.

Unlike traditional venture capital, Radial operates as a nonprofit, allowing it to prioritize long-term scientific infrastructure over immediate commercial returns. This approach addresses a critical gap in the ecosystem: while AI models are evolving rapidly, the underlying data they rely on remains fragmented and siloed. By funding these foundational layers, Chou hopes to catalyze breakthroughs in drug discovery and personalized healthcare that could define the next decade of biotechnology.

The move signals a growing trend among tech philanthropists to treat scientific data as a public good. If successful, Radial could provide the essential building blocks for a more intelligent, data-driven approach to solving humanity’s most complex medical challenges.

Seemay Chou (tech billionaire and scientist) is embarking on a mission to reshape the landscape of biological research through her new nonprofit, Radial. Backed by a $3.5 billion commitment, Chou aims to dismantle the data bottlenecks that currently hinder the development of advanced artificial intelligence in medicine.

Central to this initiative is the Diffuse project, an ambitious effort to construct a comprehensive structural biology database. By providing high-quality, standardized datasets, the project seeks to provide the foundational "fuel" required for the next generation of predictive models. Chou believes that the scarcity of organized biological data is the primary hurdle preventing a second "AlphaFold moment" in other scientific fields.

Unlike traditional venture capital, Radial operates as a nonprofit, allowing it to prioritize long-term scientific infrastructure over immediate commercial returns. This approach addresses a critical gap in the ecosystem: while AI models are evolving rapidly, the underlying data they rely on remains fragmented and siloed. By funding these foundational layers, Chou hopes to catalyze breakthroughs in drug discovery and personalized healthcare that could define the next decade of biotechnology.

The move signals a growing trend among tech philanthropists to treat scientific data as a public good. If successful, Radial could provide the essential building blocks for a more intelligent, data-driven approach to solving humanity’s most complex medical challenges.